REMINDER: Our user survey closes on Friday, please submit your responses here.
Think they are making an assumption that bad debt provision should match debtors >90 days. No reason for this to be the case if the company still believes the debt is recoverable. Though if there is a downturn the probability of recovery does reduce and so it is a vulnerability.
Why would they match?
Good RNS today
Zwarts what changed your mind. Not so long ago you said:
5.85p????
I sold these shares for 92p a couple of yrs ago.,..I bought back in at 30p and at 6p.....
Do not doubt this share....this will be massive..,..It's the predicted timescales that have driven the SP down.....I'm buying another 15ks worth late Jan.....It's going to make me a millionaire without doubt....Peeps seem to have lost track of the the product range and its potential...This thread has become the centre of abuse towards JB......crazy KTF
Pretty sure he was taking the p*** with the buy rating. Let's not forget that Hawk and Zwarts are right on a lot-greedy management, terrible track record, very high risk phase 3 trial that will make or break the company. Lot that can go wrong. Hopefully all of us I vested are aware of that and are happy to take the risk. Personally I am bullish but good to be held in check by cynics.
Also, one would expect a rub on gel to generate a placebo effect on mild Ed patients who are responding to a low dose. With more severe cases requiring a higher dose it would follow that placebo effect will reduce rather than increase.
Found it. Very disingenuous Hawk because a month later:
"Further data analysis demonstrated that in the Europe cohort1 (130 patients) Lupuzor™ plus standard of care (“Active Group”) showed statistically significant reductions (71.1% vs 48.8%, p=0.0218) in disease activity compared to placebo plus standard of care (“Comparator Group”) in 79 patients (60.8%) who were anti-dsDNA autoantibody positive (“Antibody Positive”)"
Share buybacks, interesting. Along with director buys they must think company severely undervalued, which it is
Can Hawk, Rhodi and Zwarts explain why they are negative about this share?
Is it the product market, efficacy, management, placebo effect or something else?
Discussion has descended into a slanging match so hard to work out wha the objection is.
That big enough for u GG?
Who knows what his personal financial situation is. Still a fair chunk of money.
An underwhelming reaction to director buys. Brexit I suppose